151 related articles for article (PubMed ID: 25542267)
1. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Borin MT; Chen M; Mocci S; Rubets I; Chittenden J; Aldairy W; Stroh M
Cancer Chemother Pharmacol; 2015 Feb; 75(2):401-10. PubMed ID: 25542267
[TBL] [Abstract][Full Text] [Related]
2. Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters.
Garg A; Li J; Clark E; Knott A; Carrothers TJ; Marier JF; Cortés J; Brewster M; Visich J; Lum B
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1133-41. PubMed ID: 23999693
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
4. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
[TBL] [Abstract][Full Text] [Related]
5. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
6. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Diéras V; Wildiers H; Jassem J; Dirix LY; Guastalla JP; Bono P; Hurvitz SA; Gonçalves A; Romieu G; Limentani SA; Jerusalem G; Lakshmaiah KC; Roché H; Sánchez-Rovira P; Pienkowski T; Seguí Palmer MÁ; Li A; Sun YN; Pickett CA; Slamon DJ
Breast; 2015 Jun; 24(3):182-90. PubMed ID: 25747197
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
[TBL] [Abstract][Full Text] [Related]
8. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.
Diéras V; Campone M; Yardley DA; Romieu G; Valero V; Isakoff SJ; Koeppen H; Wilson TR; Xiao Y; Shames DS; Mocci S; Chen M; Schmid P
Ann Oncol; 2015 Sep; 26(9):1904-1910. PubMed ID: 26202594
[TBL] [Abstract][Full Text] [Related]
9. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
10. Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma.
Passey C; Darbenzio R; Jou YM; Lynch M; Gupta M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1237-1244. PubMed ID: 27796540
[TBL] [Abstract][Full Text] [Related]
11. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
[TBL] [Abstract][Full Text] [Related]
12. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Durairaj C; Ruiz-Garcia A; Gauthier ER; Huang X; Lu DR; Hoffman JT; Finn RS; Joy AA; Ettl J; Rugo HS; Zheng J; Wilner KD; Wang DD
Anticancer Drugs; 2018 Mar; 29(3):271-280. PubMed ID: 29360661
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Xu N; Redfern CH; Gordon M; Eppler S; Lum BL; Trudeau C
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1251-60. PubMed ID: 25344761
[TBL] [Abstract][Full Text] [Related]
15. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Aogi K; Masuda N; Ohno S; Oda T; Iwata H; Kashiwaba M; Fujiwara Y; Kamigaki S; Ito Y; Ueno T; Takashima S
Breast Cancer Res Treat; 2011 Oct; 129(3):829-38. PubMed ID: 21805309
[TBL] [Abstract][Full Text] [Related]
16. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
17. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
18. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Brufsky AM; Hurvitz S; Perez E; Swamy R; Valero V; O'Neill V; Rugo HS
J Clin Oncol; 2011 Nov; 29(32):4286-93. PubMed ID: 21990397
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer.
Seidman AD; Conlin AK; Bach A; Moynahan ME; Lake D; Forero A; Wright GS; Hackney MH; Clawson A; Norton L; Hudis CA
Clin Breast Cancer; 2013 Aug; 13(4):239-246.e1. PubMed ID: 23829890
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
